Local Effects of Antimuscarinics

Urologic Clinics of North America

Volumn 33, Issue 4, 2006, Pages 511-518

  Masuda, Hitoshi ^a   Kim, Yong Tae ^b   Tyagi, Shachi ^c   Chancellor, Michael B ^c   de Miguel, Fernando ^c   Yoshimura, Naoki ^c  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Hanyang University   (South Korea)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; ACETYLCHOLINE; ADENOSINE TRIPHOSPHATE; ATROPINE; CAPSAICIN; CARBACHOL; CHOLINERGIC RECEPTOR; GALLAMINE; METHOCTRAMINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NITRIC OXIDE; OXYBUTYNIN; PROSTAGLANDIN; PURINE P2X RECEPTOR; TOLTERODINE; TROSPIUM CHLORIDE;

ANTICHOLINERGIC EFFECT; BLADDER EPITHELIUM; CHOLINERGIC RECEPTOR BLOCKING; DETRUSOR MUSCLE; DRUG EFFECT; EXPERIMENTAL RAT; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MECHANOTRANSDUCTION; MICTURITION; NONHUMAN; OVERACTIVE BLADDER; PARASYMPATHETIC NERVE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SPINAL GANGLION; SYSTEMIC THERAPY; UROTHELIUM;

HUMANS; MUSCARINIC ANTAGONISTS; RECEPTORS, MUSCARINIC; URINARY BLADDER, OVERACTIVE;

EID: 33749019455     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2006.06.011     Document Type: Review

References (61)

1. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-Committee of the International Continence Society. Neurourol Urodyn 21 (2002) 167-178
2. Milsom I., Abrams P., Cardozo L., et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87 (2001) 760-766
3. Yamanishi T., Chapple C.R., and Chess-Williams R. Which muscarinic receptor is important in the bladder?. World J Urol 19 (2001) 299-306
4. De Groat W.C., Booth A.M., and Yoshimura N. Neurophysiology of micturition and its modifications in animal models of human disease. In: Maggi C.A. (Ed). The autonomic nervous system nervous control of the urogenital system vol. 6 (1993), Harwood, London 227-289
5. Hegde S.S., and Eglen R.M. Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci 64 (1999) 419-428
6. Chess-Williams R., Chapple C.R., Yamanishi T., et al. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol 21 (2001) 243-248
7. Fetscher C., Fleichman M., Schmidt M., et al. M(3) muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol 136 (2002) 641-643
8. Andersson K.-E., and Yoshida M. Antimuscarinic and the overactive detrusor-which is the main mechanism of action?. Eur Urol 43 (2003) 1-5
9. Chess-Williams R. Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton Autocoid Pharmacol 22 (2002) 133-145
10. Fry C.H., Ikeda Y., Harvey R., et al. Control of bladder function by peripheral nerves: avenues for novel drug targets. Urology 63 Suppl 1 (2004) 24-31
11. Hawthorn M.H., Chapple C.R., Cock M., et al. Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro. Br J Pharmacol 129 (2000) 416-419
12. Tyagi S., Le T.S.V., Thomas C.A., et al. Differentiation stage-specific expression patterns of muscarinic receptors 1-5 mRNA in urothelium and detrusor of human bladder. J Urol 173 (2005) 325
13. Giglio D., Ryberg A.T., To K., et al. Altered muscarinic receptor subtype and functional responses in cyclophosphamide induced cyctitis in rats. Auton Neurosci Basic Clin 122 (2005) 9-20
14. Yoshida M., Miyamae K., Iwashita H., et al. Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology 63 (2004) 17-23
15. Smith P.H., Cook J.B., and Prasad E.W. The effect of ubretid on bladder function after recent complete spinal cord injury. Br J Urol 46 (1974) 187-192
16. Yossepowitch O., Gillon G., Baniel J., et al. The effect of cholinergic enhancement during filling cystometry: can edrophonium chloride be used as a provocative test for overactive bladder?. J Urol 165 (2001) 1441-1445
17. Mansfield K.J., Liu L., Mitchelson F.J., et al. Muscarnic receptor subtypes in human bladder and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol 144 (2005) 1089-1099
18. Wang P., Luthin G.R., and Ruggieri M.R. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther 273 (1995) 959-966
19. Sigala S., Mirabella G., Peroni A., et al. Differential gene expression of cholinergic muscarinic receptor subtypes in male and female normal human urinary bladder. Urology 60 (2002) 719-725
20. Yamaguchi O., Shishido K., Tamura K., et al. Evaluation of mRNAs encoding muscarinic receptor subtypes in human detrusor muscle. J Urol 156 (1996) 1208-1213
21. Wessler I., Krikpatrik C.J., and Rache K. Non-neuronal acetylcholine a locally acting molecule, widely distributed in biological systems: expression and function in humans. Pharmacol Ther 77 (1998) 59-79
22. Klapproth H., Reinheimer T., Metzen J., et al. Non-neuronal acetylcholine, a signalling molecule synthesized by surface cells of rat and man. Naunyn Schmiedebergs Arch Pharmacol 355 (1997) 513-523
23. Sastry B.V. Human placental cholinergic system. Biochem Pharmacol 53 (1997) 1577-1586
24. Conti-Fine B.M., Navaneetham D., Lei S., et al. Neuronal nicotinic receptors in non-neural cells: new mediators of tobacco toxicity?. Eur J Pharmacol 393 (2000) 279-294
25. de Groat W.C. The urothelium in overactive bladder: passive bystander or active participant?. Urology 64 (2004) 7-11
26. Maggi C.A. Prostanoids as local modulators of reflex micturition. Pharmacol Res 25 (1992) 13-20
27. Yoshimura N., Seki S., Chancellor M.B., et al. Targeting afferent hyperexcitability for therapy of the painful bladder syndrome. Urology 59 (2002) 61-67
28. Beckel J.M., Barrick S.R., Keast J.R., et al. Expression and function of urothelial muscarinic receptors and interactions with bladder nerves. Abstr Soc Neurosci (2004) 846
29. Negoita F.A., Beckel J.M., Birder L.A., et al. Effects of muscarinic receptor agonists on lumbosacral dorsal root ganglion cells. Abstr Soc Neurosci (2004) 950
30. Nishiguchi J., Hayashi Y., Chancellor M.B., et al. Detrusor overactivity induced by intravesical application of adenosine of adenosine 5′-triphosphate under different delivery conditions in rats. Urology 66 (2005) 1332-1337
31. Dussor G.O., Helesic G., Hargreaves K.M., et al. Cholinergic modulation of nociceptive responses in vivo and neuropeptide release in vitro at the level of the primary sensory neurons. Pain 107 (2004) 22-32
32. Bernardini N., Roza C., Sauer S.K., et al. Muscarinic M2 receptors on peripheral nerve endings: a molecular target of antinociception. J Neurosci 22 (2002) 1-5
33. Igawa W., Zhang X., Nishizawa O., et al. Cystometric findings in mice lacking muscarinic M2 or M3 receptors. J Urol 172 (2004) 2460-2464
34. Kim Y., Yoshimura N., Masuda H., et al. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology 65 (2005) 238-242
35. Masuda H., Hayashi Y., Masuda N., et al. Roles of bladder muscarinic receptors in the regulation of storage function in rats. J Urol 173 (2005) 149
36. Gillespie J.I., Harvey I.J., and Drake M.J. Agonist and nerve induced phasic activity in the isolated whole bladder of the guinea pig. Evidence for two types of bladder activity. Exp Physiol 88 (2003) 343-357
37. Gillespie J.I. The autonomous bladder: a view of the origin of bladder overactivity and sensory urge. BJU Int 93 (2004) 478-483
38. Wiseman O.J., Brady C.M., Hussain I.F., et al. The ultrastructure of bladder lamina propria nerves in healthy subjects and patients with detrusor hyperreflexia. J Urol 168 (2002) 2040-2045
39. Wiseman O.J., Fowler C.J., and Landon D.N. The role of the human bladder lamina propria myofibroblast. BJU Int 89 (2003) 89-93
40. Sanders K.M. A case for interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract. Gastroenterology 111 (1996) 492-515
41. Sui J.P., Rothery S., Dupont E., et al. Gap junctions and connexin expression in human suburothelial interstitial cells. BJU Int 90 (2002) 118-129
42. Salas N.A., Smith C.P., Kiss S., et al. Intravesical cholinergic receptor activated spinal ATP release in normal and chronic spinal cord injured rats. J Urol 173 (2005) 45
43. Chaiyaprasithi B., Mang C.F., Kilbinger H., et al. Inhibition of human detrusor contraction by a urothelium derived factor. J Urol 170 (2003) 1897-1900
44. Shimizu I., Kawashima K., and Hosoki K. Urodynamics in acetone-induced cystitis of anesthetized rats. Neurourol Urodyn 18 (1999) 115-127
45. Shimizu I., Kawashima K., Ishi D., et al. Effects of AH-9700, (+)-pentazocine, DTG and oxybutynin on micturition in anesthetized rats with acetone-induced cystitis. Life Sci 69 (2001) 1691-1697
46. Shenot P.J., Chancellor M.B., Rivas D.A., et al. In-vivo whole bladder response to anticholinergic and musculotropic agents in spinal cord injured rats. J Spinal Cord Med 20 (1997) 31-35
47. Sasaki Y., Hamada K., Yamazaki C., et al. Effects of NS-21, an anticholinergic drug with calcium antagonistic activity, on lower urinary tract function in a rat model of urinary frequency. Int J Urol 4 (1997) 401-406
48. Angelico P., Valasco C., Guarneri L., et al. Urodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions. BMC Pharmacol 5 (2005) 1-17
49. Zhang X., Igawa Y., Ishizuka O., et al. Effects of resiniferatoxin desensitization of capsaicin-sensitive afferents of detrusor over-activity induced by intravesical capsaicin, acetic acid or ATP in conscious rats. Naunyn Schmiedebergs Arch Pharmacol 367 (2003) 473-479
50. Andersson K.E., and Chapple C.R. Oxybutynin and the overactive bladder. World J Urol 19 (2001) 319-323
51. Kachur J.F., Peterson J.S., Carter J.P., et al. R and S enantiomers of oxybutynin: pharmacological effects in guinea pig bladder and intestine. J Pharmacol Exp Ther 247 (1988) 867-872
52. Buyse G., Waldeck K., Verpoorten C., et al. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol 160 (1998) 892-896
53. Lose G., and Norgaard J.P. Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor. BJU Int 87 (2001) 767-773
54. De Wachter S., and Wyndaele J.-J. Intravesical oxybutynin: a local anesthetic effect on bladder C afferents. J Urol 169 (2003) 1892-1895
55. Yokoyama O., Yusup A., Miwa Y., et al. Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats. J Urol 174 (2005) 2032-2036
56. Meglasson M.D., Clark M.A., Wheeler G.J., et al. Neurokinin-2 (NK-2) receptor antagonism by tolterodine tartrate. J Urol 169 (2003) 41
57. Burgard E.C., Bookout A.L., McKenna D.G., et al. Modulation of calcium currents in bladder sensory neurons by antimuscarinic agents. J Urol 170 (2005) 41
58. Ozturk H., Onen A., Guneli E., et al. Effects of methoctramine on bladder overactivity in a rat model. Urology 61 (2003) 671-676
59. 3 inactivation. J Urol 167 (2002) 397-401
60. Kim Y., Yoshimura N., Masuda H., et al. Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity. BJU Int 97 (2005) 400-403
61. Pak R.W., Petrou S.P., and Staskin D.R. Trospium chloride: a quaternary amine with unique pharmacological properties. Curr Urol Rep 4 (2003) 436-440